This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: ABT BK JNJ LULU

Stocks in this article: ABT BK JNJ LULU UA


Abbott Laboratories (ABT) was downgraded at Deutsche Bank from buy to hold. Valuation call, based on a $33 price target, Deutsche said.

Aruba Networks (ARUN) was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Growth could re-accelerate in 2013, Stifel Nicolaus said.

The Bank of New York Mellon (BK) was downgraded at Citigroup to neutral from buy. Valuation call, Citi said.

BancorpSouth (BXS) was downgraded at Keefe, Bruyette & Woods from market perform to underperform. Valuation call, based on a $12 price target, KBW said.

Cardinal Health (CAH) was upgraded at Mizuho from neutral to buy. $46 price target. Company will likely renew two major contracts in 2013, Mizuho said.

Continental Resources (CLR) was initiated with a buy rating at Deutsche Bank. $94 price target. Solid Bakken position can continue to drive growth, Deutsche said.

Cepheid (CPHD) was downgraded at Piper Jaffray from overweight to neutral. $34 price target. See further downside potential to near-term results, Piper Jaffray said.

Endo Pharmaceuticals (ENDP) was downgraded at Piper Jaffray from overweight to neutral. Opana ER is facing generic competition, Piper Jaffray said. $28 price target.

Esco Technologies (ESE) was upgraded at Robert Baird from neutral to outperform. $52 price target. Company should see higher orders in the near term, Robert Baird said.

Edwards Lifesciences (EW) was initiated with a market perform rating at JMP Securities. Company trades at a premium to its peers but has limited upside earnings potential, JMP said.

East West Bancorp (EWBC) was upgraded at Sterne Agee to buy from neutral. $26 price target. Earnings power from expense management, Sterne Agee said.

FactSet Research Systems (FDS) was initiated at Goldman Sachs with a sell rating. $79 price target. Slowing growth and emerging competition, Goldman said.

Freescale (FSL) was downgraded at JP Morgan to neutral. Company could see lower demand and lacks near-term catalysts, JP Morgan said.

Illumina (ILMN) was upgraded at Piper Jaffray from neutral to overweight. $61 price target. Company can continue to gain market share in next-generation sequencing, Piper Jaffray said.

Johnson & Johnson (JNJ) was upgraded at Deutsche Bank to buy. $82 price target. Company has a diversified business and deserves to trade at a premium valuation, Deutsche said.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs